Akihiko Koshino

6PUBLICATIONS
24CO-AUTHORS
AutoimmunityElectrochemical energy storage and conversionCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 15, 2026
Iatrogenic immunodeficiency-associated polymorphic lymphoproliferative disorder resulting in complete remission after tacrolimus withdrawal in systemic lupus erythematosus: a case report.

|Apr 02, 2026
Association of Urinary EGF with Kidney Outcomes and Effects of Sodium-Glucose Cotransporter 2 Inhibition.

Erik Moedt, Akihiko Koshino, Niels Jongs

|Sep 20, 2024
Canagliflozin and iron metabolism in the CREDENCE trial.

Akihiko Koshino, Hiddo J L Heerspink, Niels Jongs

|Jan 19, 2023
Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial.

Akihiko Koshino, Megumi Oshima, Clare Arnott

|Sep 22, 2022
Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS.

Akihiko Koshino, Meir Schechter, Taha Sen

|May 31, 2022
Mechanisms of action of the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial.

Taha Sen, Akihiko Koshino, Bruce Neal

Pageof 1

Frequent Collaborators

5 joint publications

Clare G Arnott

5 joint publications

Hiddo J L Heerspink

2 joint publications

Bruce Neal

2 joint publications

Brendon L Neuen